

JOHNSON & JOHNSON  
Form 8-K  
June 09, 2015

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 9, 2015

(Exact name of registrant as specified in its charter)

|                                                                 |                                    |                                                 |
|-----------------------------------------------------------------|------------------------------------|-------------------------------------------------|
| New Jersey<br>(State or Other Jurisdiction of<br>Incorporation) | I-3215<br>(Commission File Number) | 22-1024240<br>(IRS Employer Identification No.) |
|-----------------------------------------------------------------|------------------------------------|-------------------------------------------------|

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: 732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.02(d). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The company announced on June 9, 2015 that its Board of Directors has appointed Mary Beckerle, Ph.D., Chief Executive Officer and Director of Huntsman Cancer Institute at the University of Utah, as a Director of Johnson & Johnson. Dr. Beckerle will serve on the Board's Science, Technology & Sustainability Committee. As a non-employee director of the company, Dr. Beckerle will receive compensation as described in the "Director Compensation" section of the company's 2015 Proxy Statement. The company's press release announcing the appointment is attached to this Report as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. | Description |
|-------------|-------------|
|-------------|-------------|

|      |                                   |
|------|-----------------------------------|
| 99.1 | Press Release dated June 9, 2015. |
|------|-----------------------------------|

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 9, 2015

Johnson & Johnson

(Registrant)

By: /s/ Lacey P. Elberg

Lacey P. Elberg

Assistant Secretary